Shares of Amedisys, Inc. (NASDAQ:AMED - Get Free Report) have received an average rating of "Hold" from the five brokerages that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $100.75.
AMED has been the subject of a number of recent research reports. Stephens reiterated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Wall Street Zen lowered Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th.
View Our Latest Stock Report on AMED
Institutional Investors Weigh In On Amedisys
A number of institutional investors have recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB grew its position in shares of Amedisys by 56.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after acquiring an additional 120 shares during the period. Blue Trust Inc. grew its position in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after acquiring an additional 124 shares during the period. Fifth Third Bancorp grew its position in shares of Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after acquiring an additional 141 shares during the period. Xponance Inc. grew its position in shares of Amedisys by 3.5% during the 4th quarter. Xponance Inc. now owns 4,349 shares of the health services provider's stock valued at $395,000 after acquiring an additional 148 shares during the period. Finally, Inspire Investing LLC grew its position in shares of Amedisys by 3.6% during the 4th quarter. Inspire Investing LLC now owns 4,405 shares of the health services provider's stock valued at $400,000 after acquiring an additional 155 shares during the period. 94.36% of the stock is currently owned by institutional investors and hedge funds.
Amedisys Stock Performance
AMED stock traded down $0.08 during midday trading on Friday, reaching $93.91. The stock had a trading volume of 40,340 shares, compared to its average volume of 415,603. The stock has a market cap of $3.08 billion, a PE ratio of 37.26, a P/E/G ratio of 1.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a fifty day simple moving average of $93.39 and a two-hundred day simple moving average of $91.52. Amedisys has a 52-week low of $82.15 and a 52-week high of $98.95.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.03 EPS. As a group, equities research analysts anticipate that Amedisys will post 4.4 EPS for the current year.
About Amedisys
(
Get Free ReportAmedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading

Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.